Literature DB >> 33907800

Prophylactic sublay non-absorbable mesh positioning following midline laparotomy in a clean-contaminated field: randomized clinical trial (PROMETHEUS).

F Pizza1, D D'Antonio1, A Ronchi2, F S Lucido3, L Brusciano3, A Marvaso1, C Dell'Isola4, C Gambardella3.   

Abstract

BACKGROUND: Incisional hernia is a frequent postoperative complication after midline laparotomy. Prophylactic mesh augmentation in abdominal wall closure after elective surgery is recommended, but its role in emergency surgery is less well defined.
METHODS: This prospective randomized trial evaluated the incidence of incisional hernia in patients undergoing urgent midline laparotomy for clean-contaminated surgery. Closure using a slowly absorbable running suture was compared with closure using an additional sublay mesh (Parietex ProGrip™). Patients were randomized just before abdominal wall closure using computer-generated permuted blocks. Patients, care providers, staff collecting data, and those assessing the endpoints were all blinded to the group allocation. Patients were followed up for 24 months by means of clinical and ultrasonographic evaluations.
RESULTS: From January 2015 to June 2018, 200 patients were randomized: 100 to primary closure (control group) and 100 to Parietex ProGrip™ mesh-supported closure (mesh group). Eight patients in the control group and six in the mesh group were lost to follow-up. By 24 months after surgery, 21 patients in the control group and six in the mesh group had developed incisional hernia (P = 0.002). There was no difference between groups in the incidence of haematoma (2 versus 5; P = 0.248) and superficial wound infection (4 versus 5; P = 0.733). Multivariable analysis confirmed the role of mesh in preventing incisional hernia (odds ratio 0.11, 95 per cent c.i. 0.03 to 0.37; P  < 0.001). One patient in the mesh group required mesh removal because of deep infection.
CONCLUSION: Prophylactic mesh-augmented abdominal wall closure after urgent laparotomy in clean-contaminated wounds is safe and effective in reducing the incidence of incisional hernia. Registration number: NCT04436887 (http://www.clinicaltrials.gov). GRAPHICAL ABSTRACT: An RCT was conducted to compare the widely recommended midline laparotomy closure using a slowly absorbable running suture with closure using a sublay mesh (Parietex ProGrip™), in patients undergoing urgent midline laparotomy for clean-contaminated surgery. Patients were followed up for 24 months with clinical and ultrasonographic evaluation during outpatient visits. Prophylactic reinforcement of the midline abdominal wall, using a ProGrip™ Parietex mesh in the retromuscular position, at the time of urgent laparotomy in clean-contaminated wounds was safe and effective in reducing the incidence of incisional hernia, although larger studies with longer follow-up are required.
© The Author(s) 2021. Published by Oxford University Press on behalf of BJS Society Ltd. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Year:  2021        PMID: 33907800     DOI: 10.1093/bjs/znab068

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  3 in total

Review 1.  The effect of prophylactic mesh implantation on the development of incisional hernias in patients with elevated BMI: a systematic review and meta-analysis.

Authors:  F Pianka; A Werba; R Klotz; F Schuh; E Kalkum; P Probst; A Ramouz; E Khajeh; M W Büchler; J C Harnoss
Journal:  Hernia       Date:  2022-09-14       Impact factor: 2.920

2.  Does small bite closure reduce the incidence of incisional hernia compared to standard mass closure for midline laparotomy?

Authors:  Kareemaldin Elsamani; Ahmed Abdel Rahim; Safaa Hamid
Journal:  Ann Med Surg (Lond)       Date:  2022-08-24

3.  Nationwide analysis of laparoscopic groin hernia repair in Italy from 2015 to 2020.

Authors:  Monica Ortenzi; Emanuele Botteri; Andrea Balla; Mauro Podda; Mario Guerrieri; Alberto Sartori
Journal:  Updates Surg       Date:  2022-09-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.